{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "PRE", "regularMarketPrice": 40.74, "exchangeTimezoneShortName": "EDT", "exchangeTimezoneName": "America/New_York", "currency": "USD", "market": "us_market", "esgPopulated": false, "messageBoardId": "finmb_702442629", "gmtOffSetMilliseconds": -14400000, "shortName": "Nuvalent, Inc.", "longName": "Nuvalent, Inc.", "regularMarketChangePercent": 3.4010153, "exchange": "NMS", "regularMarketChange": 1.3400002, "regularMarketTime": 1684180805, "regularMarketDayHigh": 41.6, "regularMarketDayRange": "39.53 - 41.6", "regularMarketDayLow": 39.53, "regularMarketVolume": 146904, "regularMarketPreviousClose": 39.4, "bid": 0.0, "ask": 0.0, "bidSize": 10, "askSize": 9, "fullExchangeName": "NasdaqGS", "financialCurrency": "USD", "regularMarketOpen": 39.53, "averageDailyVolume3Month": 267806, "averageDailyVolume10Day": 246800, "fiftyTwoWeekLowChange": 33.65, "ipoExpectedDate": "2021-07-29", "averageAnalystRating": "1.8 - Buy", "tradeable": false, "cryptoTradeable": false, "fiftyTwoWeekLowChangePercent": 4.7461214, "fiftyTwoWeekRange": "7.09 - 42.99", "fiftyTwoWeekHighChange": -2.25, "fiftyTwoWeekHighChangePercent": -0.05233775, "fiftyTwoWeekLow": 7.09, "fiftyTwoWeekHigh": 42.99, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -1.61, "epsForward": -2.79, "epsCurrentYear": -2.17, "priceEpsCurrentYear": -18.774193, "sharesOutstanding": 51336200, "bookValue": 8.17, "fiftyDayAverage": 31.2172, "fiftyDayAverageChange": 9.522802, "fiftyDayAverageChangePercent": 0.30504987, "twoHundredDayAverage": 26.724, "twoHundredDayAverageChange": 14.016001, "twoHundredDayAverageChangePercent": 0.5244724, "marketCap": 2370986496, "forwardPE": -14.602151, "priceToBook": 4.9865365, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "firstTradeDateMilliseconds": 1627565400000, "priceHint": 2, "displayName": "Nuvalent", "symbol": "NUVL"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "One Broadway", "address2": "14th Floor", "city": "Cambridge", "state": "MA", "zip": "02142", "country": "United States", "phone": "857 357 7000", "website": "https://www.nuvalent.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase \u00bd clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is ongoing IND-enabling studies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 62, "companyOfficers": [{"maxAge": 1, "name": "Dr. James R. Porter Ph.D.", "age": 46, "title": "CEO, Pres & Director", "yearBorn": 1976, "fiscalYear": 2022, "totalPay": {"raw": 998020, "fmt": "998.02k", "longFmt": "998,020"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 21895162, "fmt": "21.9M", "longFmt": "21,895,162"}}, {"maxAge": 1, "name": "Prof. Matthew D. Shair Ph.D.", "age": 53, "title": "Founder, Head of Scientific Advisory Board & Director", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": {"raw": 235000, "fmt": "235k", "longFmt": "235,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Alex  Balcom CPA, M.B.A.", "age": 37, "title": "CFO & Treasurer", "yearBorn": 1985, "fiscalYear": 2022, "totalPay": {"raw": 654216, "fmt": "654.22k", "longFmt": "654,216"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 4436413, "fmt": "4.44M", "longFmt": "4,436,413"}}, {"maxAge": 1, "name": "Dr. Christopher D. Turner M.D.", "age": 53, "title": "Chief Medical Officer", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": {"raw": 714256, "fmt": "714.26k", "longFmt": "714,256"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 3111506, "fmt": "3.11M", "longFmt": "3,111,506"}}, {"maxAge": 1, "name": "Dr. Benjamin  Lane", "title": "Sr. VP of Technical Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Deborah Ann Miller J.D., Ph.D.", "age": 46, "title": "Chief Legal Officer & Sec.", "yearBorn": 1976, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Matthew  Metivier", "title": "VP of HR", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Darlene  Noci", "age": 45, "title": "Chief Devel. Officer", "yearBorn": 1977, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Henry  Pelish Ph.D.", "title": "Sr. VP of Drug Discovery", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. John  Soglia Ph.D.", "title": "Sr. VP of Translational Devel.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 7, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 10, "overallRisk": 9, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}